Literature DB >> 2027299

Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3.

K Ohyashiki1, H Fujieda, J Miyauchi, J H Ohyashiki, T Tauchi, M Saito, S Nakazawa, K Abe, K Yamamoto, S C Clark.   

Abstract

A cell line, designated HAL-01, was established from the blood cells of a patient with acute lymphoblastic leukemia (ALL) with a myeloid-associated marker. Both the cell line and the patient's fresh leukemia cells had the chromosomal translocation t(17;19)(q21;p13). Morphologically and cytochemically, the cells were lymphoid in appearance. Immunophenotyping of the donor's leukemia cells revealed that they express B lineage antigens (CD10+, CD19+, CD20+, CD22+); the myeloid-associated antigen (CD13) detected in the donor's leukemia cells was not expressed by the established cell line. The HAL-01 cells have a rearrangement of the immunoglobulin heavy chain gene, while the T-cell receptor beta-chain genes remain in the germline configuration. The gene encoding the binding proteins for the kappa-light chain enhancer (kappa E2), which is involved in pre-B-ALL cells with the t(1;19) (q23;p13) translocation, is not rearranged in the cell line. The HAL-01 cells were transplantable into the peritoneum of untreated nude mice where they grew as an ascites tumor. The growing tumor cells also infiltrated lymph nodes, liver, spleen, kidney, and bone marrow without exhibiting a particular change in the morphology of the neoplastic cells. Clonogenic assay in methylcellulose culture demonstrated that the proliferation of the HAL-01 cells was suppressed by interleukin-3 (IL-3) in a dose-dependent fashion, with maximum inhibition occurring at concentrations greater than 100 U/ml. Treatment with IL-3 reduced the number of viable cells as well as induced morphological changes without concomitant changes in cytochemical reactions or immunophenotypic expression. Reduction of 3H-thymidine incorporation by exposure of IL-3 was blocked by the pretreatment of neutralizing anti-IL-3 antibody, but not by neutralizing anti-TGF-beta antibody. Thus, HAL-01 is a unique ALL cell line exhibiting proliferative suppression by IL-3 that may prove useful in studying the interactions of cytokines in ALL.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2027299

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice.

Authors:  K S Smith; J W Rhee; L Naumovski; M L Cleary
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

2.  Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.

Authors:  Xiaobo Hu; Hui Wei; Laiman Xiang; Oleg Chertov; Alan S Wayne; Tapan K Bera; Ira Pastan
Journal:  Leuk Res       Date:  2013-08-13       Impact factor: 3.156

3.  Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.

Authors:  Rachel M A Linger; Alisa B Lee-Sherick; Deborah DeRyckere; Rebecca A Cohen; Kristen M Jacobsen; Amy McGranahan; Luis N Brandão; Amanda Winges; Kelly K Sawczyn; Xiayuan Liang; Amy K Keating; Aik Choon Tan; H Shelton Earp; Douglas K Graham
Journal:  Blood       Date:  2013-07-16       Impact factor: 22.113

4.  Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Authors:  Rachel M A Linger; Deborah DeRyckere; Luis Brandão; Kelly K Sawczyn; Kristen M Jacobsen; Xiayuan Liang; Amy K Keating; Douglas K Graham
Journal:  Blood       Date:  2009-07-30       Impact factor: 22.113

5.  A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.

Authors:  Takeshi Inukai; Xiuru Zhang; Takeshi Kameyama; Yukiko Suzuki; Kazuhito Yoshikawa; Itaru Kuroda; Atsushi Nemoto; Koshi Akahane; Hiroki Sato; Kumiko Goi; Kazunori Nakamoto; Jun-ichi Hamada; Mitsuhiro Tada; Tetsuya Moriuchi; Kanji Sugita
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047

6.  t(17;19) in Children with Acute Lymphocytic Leukemia: A Report of 3 Cases and a Review of the Literature.

Authors:  Katherine A Minson; Pinki Prasad; Susan Vear; Scott Borinstein; Richard Ho; Jennifer Domm; Haydar Frangoul
Journal:  Case Rep Hematol       Date:  2013-01-03

7.  Growth stimulation of primary B cell precursors by the anti-phosphatase Sbf1.

Authors:  I De Vivo; X Cui; J Domen; M L Cleary
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.